Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The First Affiliated Hospital of Dalian Medical University
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. Lupus nephritis (LN) is one of the most serious complications of SLE. The current clinical treatments of LN mainly include steroids and immunosuppressive drugs, but drug side effects are obvious.
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Meeting the 1997 American College of Rheumatology (ACR) classification criteria of SLE.
age 18-60 years.
of either sex and of any ethnicity.
Lupus nephritis (LN) group: (1) Receiving more than 6 months of regular treatment, 24-hour urine protein ≥ 1.0 g, serum creatinine ≥1.5 mg/dL; (2) renal biopsy: class III, IV or V LN included, and class VI excluded.
After conventional treatment (glucocorticoid therapy and immunosuppressive drugs) prior to grouping, SLEDAI scores ≥ 10.
Receiving 12 months of treatment while using birth control.
Provision of informed consent.
You may not be if
Poor blood pressure control by drug treatment (≥ 160/100 mmHg)
Abnormal hepatic function (a 3-fold increase in alanine aminotransferase level relative to normal liver).